We can then provide our patients with a treatment regimen aimed at helping them achieve better outcomes.” “The level of detail provided by the Ga-68 DOTATATE scan allows us to more accurately stage the disease. “The key to effective treatment of a rare cancer like neuroendocrine is accurate diagnosis,” says Allen Cohn, MD, co-director of Medical Services of The Neuroendocrine Institute at Rocky Mountain Cancer Centers. The condition historically has been difficult to diagnose, and the cancer is not well recognized or understood across the medical community. They primarily affect abdominal and respiratory organs, including the stomach, pancreas, intestines, and lungs. The tumors are slow-growing but very likely to spread. Nearly 10,000 people in the United States are diagnosed with NETs each year. “The information is critical for me to do the best possible surgery for patients,” Dr. RMCC neuroendocrine tumor surgeon, and internationally recognized disease expert, Eric Liu, MD, FACS, was instrumental in research that led to the approval of the gallium diagnostic test. The Ga-68 DOTATATE scan allows surgeons to pinpoint the precise location of tumors before beginning surgery. Because the gallium DOTATATE binds strongly to the receptors of neuroendocrine tumor cells, it effectively detects tumors and metastases, not seen on other standard scans, and reveals the locations of tumors. Marketed under the name Netspot™, gallium 68 DOTATATE is a radioactive diagnostic agent used in positron emission tomography (PET) imaging.
Food and Drug Administration (FDA) recently approved the test.
(November 15, 2016) – Rocky Mountain Cancer Centers ( RMCC), a practice in The US Oncology Network, is the first in the Rocky Mountain region, and one of only a handful of sites in the United States, to offer the newly approved Ga-68 DOTATATE PET/CT for patients with neuroendocrine tumors (NETs).
0 kommentar(er)
